Market Place
Sourcing Support
Alnylam`s FDA Acceptance of Vutrisiran sNDA for ATTR Amyloidosis
25 Nov 2024 //
BUSINESSWIRE
AstraZeneca`s breast cancer drug combination fails in late-stage trial
19 Jun 2024 //
REUTERS
AstraZeneca`s Truqap (capivasertib) Receives Approval In Europe
17 Jun 2024 //
EMA
CHMP recommends eight new drug approvals, six label expansions
27 Apr 2024 //
ENDPTS
TRUQAP™ (capivasertib) Now Available from Onco360
29 Nov 2023 //
BUSINESSWIRE
Astex Earns AstraZeneca Milestone for Truqap Approval
20 Nov 2023 //
CONTRACT PHARMA
TRUQAP™ (capivasertib) plus fulvestrant approved in the US
17 Nov 2023 //
BUSINESSWIRE
US FDA approves AstraZeneca`s breast cancer drug combination
17 Nov 2023 //
REUTERS
Capivasertib in combination with FASLODEX granted Priority Review in the US
12 Jun 2023 //
BUSINESSWIRE
AstraZeneca hails positive findings in breast cancer drug trial
09 Dec 2022 //
PRESS RELEASE
Capivasertib plus Faslodex significantly improved progression-free surviva
27 Oct 2022 //
PHARMABIZ
AstraZeneca extends run of trial successes with breast cancer drug results
27 Oct 2022 //
BIOPHARMADIVE
Capivasertib plus FASLODEX improved progression-free survival vs. FASLODEX
26 Oct 2022 //
BUSINESSWIRE
AstraZeneca scores breast cancer wins for AKT and SERD drugs
26 Oct 2022 //
FIERCEBIOTECH
Breast cancer drug capivasertib enters major trial
25 Jun 2020 //
ICR
A Spark Of Good News For Precision Oncology In Breast Cancer
14 Nov 2018 //
FORBES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.